Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.39 |
| ▸ | NCF1 | P14598 | 4/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15452336 | 0.93 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19BCHEACHE | |
| SCHEMBL15459688 | 0.89 | CYP1A2 (0.39) | CYP1A2CYP2C9CYP2C19BCHEACHE | |
| SCHEMBL10137170 | 0.86 | BCHE (0.37) | CYP1A2CYP2C9CYP2C19BCHEACHE | |
| SCHEMBL4568721 | 0.83 | GSK3B (0.40) | LTA4H | |
| SCHEMBL10137154 | 0.83 | PTPN11 (0.44) | THRATHRBCNR2 | |
| SCHEMBL15452271 | 0.81 | THRA (0.35) | CYP1A2CYP2C9CYP2C19BCHEACHE | |
| SCHEMBL17733172 | 0.80 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19BCHEACHE | |
| SCHEMBL10070993 | 0.78 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19BCHEACHE | |
| SCHEMBL13556904 | 0.77 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2C19BCHEACHE | |
| SCHEMBL15452270 | 0.77 | PTPN11 (0.46) | THRATHRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463280-B1 | CHROMENE COMPOUND | TOKUYAMA CORP (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| EP-2463280-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | CYP1A2 709/4885CYP2C9 475/4885CYP2C19 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.